• Users Online: 167
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 9  |  Issue : 4  |  Page : 244-249

Comparative therapeutic efficiency of remdesivir in COVID in a tertiary care center


Department of Medicine, Bowring and Lady Curzon Hospital and Research Institute, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Mahendra Munirathnam
No. 44, 4th Main, 4th East Cross, Riches Garden, Kalkare Road, Rammurthy Nagar, Bengaluru - 560 016, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ajim.ajim_3_21

Rights and Permissions

Introduction: The catastrophic effects of corona in 2020 identified the use of broad-spectrum antiviral remdesivir (RDV). The beneficial effects of RDV are not proven and documented in many trials in COVID. Materials and Methods: Reverse transcriptase–polymerase chain reaction (RT-PCR)-confirmed cohort cases of COVID were retrospectively analyzed for outcomes including mortality and clinical improvement with and without RDV during the period September 21, 2020–October 9, 2020. The data were analyzed statistically for outcome in COVID. The present study was carried out to evaluate the clinical benefits of RDV and its outcomes in COVID. Results: A total of 91 RT-PCR positive COVID patients were grouped into 37 RDV (41%) and 54 non-RDV (51%). The mean age was 51 and 55. Male-to-female ratio of 67:32 and 65:35 in the RDV and non-RDV groups was found, indicating male predominance in the study. The recovery time for COVID was 11 days with a cure rate of 78% in the RDV group, while it was 21 days with 98% in the non-RDV group. A statistical significant association was found between RDV and the need for oxygen support (hypoxic patients) and noninvasive ventilation (NIV). Twenty-seven percent in RDV group needed NIV (P = 0.009). Morbidity and mortality were 19% (7) and 22% (8) and 7% (4) and 2% (1) in the RDV and non-RDV groups, respectively. Conclusion: RDV use in COVID was associated with increased mortality (22% vs. 2%) but reduced duration of hospitalization by 50% as compared to non-RDV group. Early identification of hypoxia plays an important role in COVID management for initiating RDV treatment.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed104    
    Printed0    
    Emailed0    
    PDF Downloaded13    
    Comments [Add]    

Recommend this journal